CA3103474A1 - Glycosylated comp pilin variants, methods of making and uses thereof - Google Patents

Glycosylated comp pilin variants, methods of making and uses thereof Download PDF

Info

Publication number
CA3103474A1
CA3103474A1 CA3103474A CA3103474A CA3103474A1 CA 3103474 A1 CA3103474 A1 CA 3103474A1 CA 3103474 A CA3103474 A CA 3103474A CA 3103474 A CA3103474 A CA 3103474A CA 3103474 A1 CA3103474 A1 CA 3103474A1
Authority
CA
Canada
Prior art keywords
seq
comp
protein
serine residue
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3103474A
Other languages
English (en)
French (fr)
Inventor
Christian HARDING
Mario Feldman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxnewmo LLC
Original Assignee
Vaxnewmo LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxnewmo LLC filed Critical Vaxnewmo LLC
Publication of CA3103474A1 publication Critical patent/CA3103474A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA3103474A 2018-06-16 2019-06-14 Glycosylated comp pilin variants, methods of making and uses thereof Pending CA3103474A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862685970P 2018-06-16 2018-06-16
US62/685,970 2018-06-16
US201862783971P 2018-12-21 2018-12-21
US62/783,971 2018-12-21
PCT/US2019/037251 WO2019241672A2 (en) 2018-06-16 2019-06-14 Glycosylated comp pilin variants, methods of making and uses thereof

Publications (1)

Publication Number Publication Date
CA3103474A1 true CA3103474A1 (en) 2019-12-19

Family

ID=68843212

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3103474A Pending CA3103474A1 (en) 2018-06-16 2019-06-14 Glycosylated comp pilin variants, methods of making and uses thereof

Country Status (7)

Country Link
US (2) US11932670B2 (https=)
EP (1) EP3806881B1 (https=)
JP (2) JP2021528059A (https=)
AU (1) AU2019287659B2 (https=)
CA (1) CA3103474A1 (https=)
ES (1) ES3051337T3 (https=)
WO (1) WO2019241672A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3262077B1 (en) 2015-02-26 2025-06-04 Vaxnewmo Llc Acinetobacter o-oligosaccharyltransferases and uses thereof
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2019241672A2 (en) 2018-06-16 2019-12-19 Vaxnewmo Llc Glycosylated comp pilin variants, methods of making and uses thereof
ES3055827T3 (en) 2018-12-21 2026-02-16 Vaxnewmo Llc O-linked glycosylation recognition motifs
EP4171625A2 (en) * 2020-06-25 2023-05-03 GlaxoSmithKline Biologicals SA Klebsiella pneumoniae o-antigen vaccine
EP4271417A4 (en) * 2020-12-31 2024-11-27 Vaxnewmo Llc GLYCOSYLATED KLEBSIELLA PNEUMONIAE O-ANTIGEN AND METHODS OF PREPARATION AND USES THEREOF
CA3215046A1 (en) * 2021-04-28 2022-11-03 Vaxnewmo Llc Minimal sequons sufficient for o-linking glycosylation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2671709C (en) 2006-12-13 2016-08-16 The Governors Of The University Of Alberta Methods and systems for o-glycosylating proteins
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
EP2742355B1 (en) 2011-08-12 2018-12-19 The Governors of the University of Alberta Method of diagnosing bacterial infections using bacterial glycoproteins
CN104080921A (zh) 2011-11-04 2014-10-01 康奈尔大学 一种用于糖蛋白合成的基于原核生物的无细胞系统
CN110423716A (zh) 2012-10-12 2019-11-08 葛兰素史密丝克莱恩生物有限公司 宿主细胞修饰方法
CA2889767C (en) * 2012-11-07 2021-09-21 Glycovaxyn Ag Production of recombinant vaccine in e. coli by enzymatic conjugation
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014195011A1 (en) 2013-06-04 2014-12-11 Icon Genetics Gmbh Methods of modulating n-glycosylation site occupancy of plant-produced glycoproteins and recombinant glycoproteins
US9988426B2 (en) 2014-09-18 2018-06-05 University Of Maryland, Baltimore Broad spectrum conjugate vaccine to prevent Klebsiella pneumoniae and Pseudomonas aeruginosa infections
LT3240895T (lt) 2014-12-30 2022-04-11 Glaxosmithkline Biologicals S.A. Kompozicijos ir būdai, skirti baltymų glikozilinimui
EP3262077B1 (en) * 2015-02-26 2025-06-04 Vaxnewmo Llc Acinetobacter o-oligosaccharyltransferases and uses thereof
US11279943B2 (en) 2017-01-17 2022-03-22 Bioapplications Inc. Recombinant vector for expressing target protein in plant cell
EP3492481A1 (en) 2017-11-30 2019-06-05 Vaxxilon AG Vaccine against klebsiella pneumoniae
WO2019241672A2 (en) 2018-06-16 2019-12-19 Vaxnewmo Llc Glycosylated comp pilin variants, methods of making and uses thereof
US20220054632A1 (en) 2018-12-12 2022-02-24 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
ES3055827T3 (en) 2018-12-21 2026-02-16 Vaxnewmo Llc O-linked glycosylation recognition motifs

Also Published As

Publication number Publication date
AU2019287659A1 (en) 2021-01-07
US11932670B2 (en) 2024-03-19
US20240262870A1 (en) 2024-08-08
WO2019241672A2 (en) 2019-12-19
JP2024079845A (ja) 2024-06-11
ES3051337T3 (en) 2025-12-26
EP3806881A2 (en) 2021-04-21
JP2021528059A (ja) 2021-10-21
AU2019287659B2 (en) 2025-02-20
WO2019241672A3 (en) 2020-02-06
US12577280B2 (en) 2026-03-17
US20210324017A1 (en) 2021-10-21
EP3806881A4 (en) 2022-07-27
EP3806881B1 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
US12577280B2 (en) Glycosylated comp pilin variants, methods of making and uses thereof
US12350342B2 (en) O-linked glycosylation recognition motifs
WO2017067964A1 (en) P. aeruginosa pcrv-linked antigen vaccines
JP7551618B2 (ja) Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
US20240066109A1 (en) Klebsiella Pneumoniae O-Antigen Glycosylated Proteins and Methods of Making and Uses Thereof
US20240207383A1 (en) Minimal Sequons Sufficient for O-Linking Glycosylation
CN120897997A (zh) 用于生产具有与第二多肽配偶体的异肽键的糖缀合物多肽的组合物和方法以及这些糖缀合物多肽的用途
JP2025535072A (ja) モラクセラ科ｏ結合型オリゴ糖転移酵素、糖鎖付加断片、及びそれらの使用
Mayer et al. A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host
WO2024175620A1 (en) Immunogenic composition
EP4452308A1 (en) Vaccine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220914

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20241009

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20241112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250102

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250326

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250326

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250526

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250526

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250620

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251020

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251215

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251215